Cyclodextrin in Pharma Market Size, Share, Growth, and Industry Analysis, By Type (Alpha-Cyclodextrin, Beta-Cyclodextrin and Gamma-Cyclodextrin), By Application (Pharmaceuticals, Drug Delivery, Nutraceuticals, Cosmetics and Biotechnology), and Regional Insights and Forecast to 2033

•   
•   
  

  Request a Free sample to learn more about this report

    

CYCLODEXTRIN IN PHARMA MARKET OVERVIEW

The global Cyclodextrin in Pharma market size was USD 206.11 million in 2025 and is projected to touch USD 416.15 million by 2033, exhibiting a CAGR of 8.12% during the forecast period. 

The pharmaceutical industry extensively applies cyclodextrins; they have been utilized in improving the solubility of a drug, stability, and availability of the drug. The well-known pharma example is 2-hydroxypropyl-beta-cyclodextrin (2HPbetaCD) that is active in several experimental drugs such as the VAR 200 used in the treatment of kidney-related diseases such as focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease. They are considered to have a good risk/benefit profile and are in clinical investigation as treatment of a variety of indications, in some cases specifically focused on the encapsulation of poorly soluble drug molecules, improving the delivery and therapeutic effect.

The interest of the pharmaceutical industry in the use of cyclodextrin in drug delivery and drug formulation is quite impressive, leading to an explosion in the cyclodextrin drug pharmaceutical marketplace. Cyclodextrin as a Cyclodextrins, with its complicated chemical nature, has found application as a diverse pharmaceutical excipient, which vastly enhances solubility, stability, and bioavailability of drugs due to the inclusion complexes formed with guest molecules by cyclodextrin. Being hydrophilic on the outside and lipophilic on the inside, cyclodextrin can bind with drug molecules of impending size, resulting in better curative effects and minimal side effects. Rapid shift to precision medicine and individualized drug delivery is increasing cyclodextrin-based formulations in the pharmaceutical industry. Now, over 130 approved pharmaceutical products of cyclodextrins or their derivatives are in the business world, as there are hydroxypropyl, sulfobutyl, random methylated, and sulfolipid derivatives of cyclodextrins.

RUSSIA-UKRAINE WAR IMPACT

Cyclodextrin in the Pharma Market Has Experienced Supply Chain Challenges Due to Eastern European Manufacturing Dependencies during the Russia-Ukraine War

The Russia-Ukraine war had a notable impact on the Cyclodextrin in Pharma market share, particularly due to the war in Russia and Ukraine has influenced the cyclodextrin-based pharmaceutical industry, especially the areas of supply chains as well as the availability of raw materials. Both countries, Russia and Ukraine, have been historically involved in chemical production and supply chain in the pharmaceutical industry, and the war has disrupted the traditional sources of production of cyclodextrin. The unpredictability of the war has caused raw material prices to get ever more volatile and thrown pharmaceutical firms into the need to spread their supplier base.  

LATEST TRENDS

Growing Applications in Drug Delivery and Precision Medicine to Drive Market Growth

The current trend in the pharmaceutical cyclodextrin market is the increased popularity of high-tech drug delivery systems and precision medicines, as more people recognize the potential that cyclodextrins have as therapeutic agents. There is an enormous growth in the demand for cyclodextrin-based formulation in bioavailability enhancement and in controlled release systems because of their better profile of drug complexation and safety. The development of cyclodextrin derivatives, like ready-to-use formulation and specific pharmaceutical complexes, is becoming very popular on the market. Further, the cyclodextrin applications to new therapeutic areas related to neurodegenerative diseases and rare genetic disorders offer tremendous potential for expanding the clinical attractiveness of the technology, which is also on the rise in the industry. More companies are implementing sustainable manufacturing and environmentally friendly practices when they produce their brands; as more pharmaceutical companies and regulators become more environmentally conscious as a pharmaceutical practice, they put more emphasis on environmental effects, and the sustainability of drug development grows.  

•   
•   
  

  Request a Free sample to learn more about this report

    

CYCLODEXTRIN IN PHARMA MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into Alpha-Cyclodextrin, Beta-Cyclodextrin and Gamma-Cyclodextrin

• Alpha-Cyclodextrin: Has a smaller cavity to be suitable to solubilize and preserving smaller drug molecules. Building popularity in the times of drug delivery systems and utilization as a nutraceutical compound, scientific studies are underway on its cholesterol-reducing properties.

• Beta-Cyclodextrin: Most commonly used owing to its ideal cavity and cost-effectiveness, it is used extensively in marketed drugs to increase the solubility and stability of medium-sized APIs.

• Gamma-Cyclodextrin: Its natural largest cavity makes applicability applicable to entrap larger or sensitive biologic molecules, which are essential in drug delivery at advanced levels, such as macromolecules and gene therapies.

By Application

Based on application, the global market can be categorized into Pharmaceuticals, Drug Delivery, Nutraceuticals, Cosmetics and Biotechnology

• Pharmaceuticals: Its natural largest cavity makes applicability applicable to entrap larger or sensitive biologic molecules, which are essential in drug delivery at advanced levels, such as macromolecules and gene therapies.

• Drug Delivery: The single biggest application- cyclodextrins are critical solubility, bioavailability and stability excipients in oral, parenteral, ophthalmic, and topical dosage forms

• Nutraceuticals: Cyclodextrin complexes provide controlled release, targeted release, mucosal penetration, taste masking and stabilization, which makes them a necessity in current systems of delivery, such as injectables and new formulations of biologics.

• Cosmetics: In personal care, it is also used in fragrance encapsulation, stability of active ingredients and controlled release (e.g. vitamins, retinol) and increasingly in skincare and haircare.

• Biotechnology: The cyclodextrin subsets, γ- and modified cyclodextrins, have found targeted use in biotechnology products, including macromolecule carriers, gene-delivery vectors and protein stabilization, showing promise in novel therapies.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Increasing Demand for Enhanced Drug Delivery Solutions to Boost the Market

A factor in the Cyclodextrin in Pharma market growth is the Increased demand for sophisticated drug delivery technologies and solutions that stimulate the enhancement of bioavailability is a major reason that has promoted the growth of the cyclodextrin pharmaceutical markets. In recent years, pharmaceutical companies have been developing new ways of enhancing the solubility, stability, and efficacy of drugs. These needs of the industry are ideally measured with cyclodextrins, whose formation of inclusion complexes and benefits in drug characteristics are quite exclusive. Increasing sophistication of drug delivery systems leads to huge future demand of cyclodextrin-based formulations since pharmaceutical companies keep on developing ever-smarter and more efficacious methods of drug delivery as well as avoiding side-effects to optimize therapeutic results, an aspect that determines substantial growth of this market in both mature and developing lines of therapeutics.

Growing Prevalence of Poorly Water-Soluble Drugs to Expand the Market

The pharmaceutical cyclodextrin market is also driven by the rising trend in the growing number of poorly water-soluble drug candidates. The pharmaceutical industry is challenged with formulation issues during the development and manufacture of a chemical due to poor aqueous solubility of more than 40 per cent of the new chemical entities. Cyclodextrin technology can effectively resolve the formulation issues of the pharmaceutical industry. The cyclodextrins offer necessary solutions to improve the solubility and bioavailability of drugs that can otherwise not be developed in clinics.

Restraining Factor

High Development Costs and Regulatory Complexity to Potentially Impede Market Growth

One of the main negative forces in the cyclodextrin pharmaceutical market is the overpowering expense and intricacy in creating cyclodextrin structures. All the complexities of the formation of an inclusion complex demand massive investment in research and development, manufacturing expertise, and regulatory compliance. Besides, effective safety and efficacy testing of cyclodextrin-drug complexes may prolong product development time and burden expenses. These attributes might restrain access to the smaller firms and might retard cyclodextrin technology implementation in some of the market divides especially in the cost-oriented merchant of the therapies or in the developing economies.

Expanding Applications in Rare Diseases and Precision Medicine Create Opportunity for the Product in the Market

Opportunity

The increasing attention on rare disease therapies and precision medicine is an enormous opportunity for the cyclodextrin pharmaceutical market. Cyclodextrin technology has distinct, beneficial impacts when it comes to the development of treatment for rare genetic diseases, neurodegenerative diseases, and other niche therapeutic spheres where an increase in drug delivery and bioavailability is a major component of therapeutic success. This is one of the markets that fetch high prices and regulatory incentives, thereby making cyclodextrin-based innovations very lucrative.

With the pharmaceutical business maintaining its focus and investment in the development of orphan drugs and personalized medicines strategy, the technology of cyclodextrins will likely reap substantial value in these billion-dollar-value markets with their high growth potential.

Potential Safety Concerns and Regulatory Scrutiny Could Be a Potential Challenge for Consumers

Challenge

Cyclodextrins are widely accepted safe pharmaceutical excipients, but possible high-dose and derivative concerns may limit the growth of the market. Newer cyclodextrin formulations have come under greater scrutiny from the regulatory bodies, especially when there is the introduction of new derivatives or new delivery mechanisms. A few people can have a sensitivity to some cyclodextrin formulations, and some concerns about the chronic consequences of long-term effects of using cyclodextrin need to be continuously assessed.

Such safety measures require a thorough pre-clinical and clinical testing, which can raise the cost of development and the duration of development. Also, differing so-called regulatory requirements across world markets can prove to be a hindering factor towards the development and commercialization of its global products, which can inhibit market development in selected markets.

•   
•   
  Request a Free sample to learn more about this report

    

CYCLODEXTRIN IN PHARMA MARKET REGIONAL INSIGHTS

• North America

North America has the biggest regional demand for cyclodextrin pharmaceuticals and which is attributed to the developed pharmaceutical infrastructure and a high investment in drug delivery systems. Research and development would be an advantage of the region, and many pharmaceutical companies are working on the formulation of cyclodextrin with different applications in therapy. The FDA support through the regulatory environment on innovative drug delivery systems has helped in market expansion and availability of the key players in the manufacture of cyclodextrin, and the research and development facility has enhanced the market in the region. Particularly, the United States Cyclodextrin in Pharma market has demonstrated a high level of adaptations of cyclodextrin technology, with several products already approved by the FDA, featuring cyclodextrins intended to treat several medical conditions. A healthy healthcare infrastructure and a large healthcare expenditure put the U.S. market in an advantageous position in touting the use of high-tech pharmaceutical products such as drug delivery systems based on cyclodextrin.

• Europe

Europe is a very important and developed market for cyclodextrin drugs, and there are well-established regulations on the cyclodextrin based products development and commercialization. Its pharmaceutical industry is established, and the region has a rich experience in the application of cyclodextrin, since it took place already at the very beginning of cyclodextrin technology. Cyclodextrin-containing products have had regulatory pathways well-spelt out by the regulatory agencies in Europe, making the development of the market easier and the products get approved. The nature of the region on pharmaceutical innovation and quality has led to the persistence in the demand for cyclodextrin-based solutions in particularly in the biological activity improvement as well as specialized drug delivery systems. Nonetheless, the economic demands and cost control measures on healthcare, in some countries in Europe, have imposed prices that can influence the expansion of the market in some sectors.  

•  Asia

Asia, especially countries such as Japan and China, is a fast-developing market for cyclodextrin pharmaceuticals with great prospects to increase it. Japan has also led in the use of cyclodextrin in pharmaceutics, with at least twelve pharmaceutical preparations that are in the market containing cyclodextrins. The region has an advantage of rising pharmaceutical industries, the development of healthcare capital, and improved demand for superior drug delivery technologies. The cyclodextrin market in China has huge growth potential due to the increase of the pharmaceutical manufacturing industry in China, as well as government funding toward pharmaceutical industry advancements. Due to the high number of patients and increased access to health delivery in the region, there is a demand for better pharmaceutical formulations, and that is why cyclodextrins will be a device that can contribute to meeting various therapeutic demands.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market Through Innovation and Market Expansion

Major competitors are evolving the cyclodextrin pharmaceutical market by means of intelligent innovation and thorough market expansion programs. These firms are deploying state-of-the-art research and development procedures that will improve the cyclodextrin formulation technologies and widen the therapeutic applications of the drug. They are also coming up with specific cyclodextrin derivatives and novel systems of delivery to meet particular pharmaceutical problems and needs of the patient. Further, they are also using strategic collaborations with pharma firms and research centre to fast-track product development and market penetration. These players are investing in the manufacturing capabilities and reaching global distribution networks and new promising areas to treat, thus making growth and setting new standards in the cyclodextrin pharmaceutical industry.

List Of Tops Cyclodextrin In Pharma Companies

• Wacker Chemie AG (Germany)
• Roquette Frères (France)
• Cyclolab R&D Laboratory (Hungary)
• Ashland (U.S.)
• Mallinckrodt (Ireland)
• Sumitomo Chemical Co., Ltd. (Japan)
• Kleptose (Belgium)
• CTD Holdings, Inc. (U.S.)
• Gan & Lee Pharmaceuticals (China)
• Zibo Qianhui Biotechnology Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENT

October 2024: ZyVersa Therapeutics ripped off a VAR 200 (2-hydroxypropyl-beta-cyclodextrin) program, aimed at Phase 2a clinical trials to treat diabetic kidney disease, and attested to the widening use of cyclodextrin technology in kidney diseases. The breakthrough is a major step towards the application of cyclodextrin technology in the management of chronic kidney diseases, with the possible expansion to the management of various renal disorders, such as focal segmental glomerulosclerosis and Alport Syndrome.  

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The cyclodextrin pharmaceutical market is poised to continue growing through growing demand for advanced technology in drug delivery, growing uses in precision medicine, and cyclodextrin derivatives and formulation technology. Although such factors as cost of development and regulatory complexity are some of the challenges that the market faces, the market has a high level of adoption in the pharmaceutical industry and clinical integrity in its use across various therapeutic areas. Major market players are emerging by uniting technology with strategic therapeutic expansion, thus improving their accessibility and maturity of the cyclodextrin-based pharmaceutical solutions. With the focus on healthcare systems being on enhanced therapeutic results and patient-centre medicine, the cyclodextrin pharmaceutics market is likely to exceed, with more innovation and a wider range of clinical use leading to the future development of the market.